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Abstract  Background: Despite guidelines that 
recommend strongly against Sliding Scale Insulin (SSI) it 
continues to be the most commonly insulin regimen used in 
hospitals to treat hyperglycemia. In addition to being 
reactionary to a glucose that has already increased, SSI offers 
practical challenges in the randomness of the doses of insulin 
prescribed and often a disconnect with glucose testing that 
should be occurring in congruence to the insulin dosing. 
While many clinical trials have shown improved glycemic 
control in critical care patients receiving intravenous insulin; 
few studies have demonstrated the efficacy of subcutaneous 
(SQ) insulin in this setting. In this study, we have evaluated 
the safety and efficacy of SQ insulin administration utilizing 
a computerized program, the Clarian GlucoStabilizer™ 
Subcutaneous Program (CGS-SQ) in the intensive care unit 
(ICU). This program is designed to overcome some of the 
most common barriers of SQ insulin delivery, those of dose 
calculation and timing.  
Methods: A computerized SQ insulin delivery program -The 
Clarian GlucoStabilizer™ Subcutaneous Program 
(CGS-SQ)- was made available to ICU practitioners,  
facilitating standardized calculation of insulin doses and 
incorporating reminder alarms for blood glucose (BG) 
testing. This program used three defaults Insulin Sensitivity 
Factors (ISF) and Insulin to Carbohydrate Ratios (CR) to 
calculate insulin doses.  Additionally, there is an option for 
practitioner determined ISF and ICR. Patients, aged ≥ 18 
years, initiated on the CGS-SQ and admitted to the (ICU) 
were eligible for inclusion in this retrospective evaluation.  
Patients were divided into four groups based on initial 
insulin sensitivity factor (ISF) and carbohydrate ratio (CR).  
Three of the groups used a default ISF and CR; ISF 60, CR 
15; ISF 30, CR 10 and ISF 15, CR 8. These groups were 
compared with those where the practitioner specified an 
individualized ISF and CR, referred to as PDS (practitioner 
defined setting). Primary endpoints included: mean glucose, 
time to target glucose, hyperglycemic and hypoglycemic 
events. 
Results: In the 1,384 patients identified, patients initiated 
with a predefined setting had lower mean glucose compared 
to patients with PDS (ISF 60, CR 15: 135 mg/dL vs. ISF 30, 
CR 10: 140 mg/dL vs. ISF 15, CR 8: 134 mg/dL vs. PDS: 
143 mg/dL; p < 0.0001). Patients in the default settings had 
shorter time to target glucose and decreased incidence of 
hyperglycemia and hypoglycemia. 
Conclusions: Using a system of computerized prompts with 
standardization of insulin dose calculation, SQ insulin can be 
effectively used in the treatment of ICU patients to target BG 
of 100-150 mg/dL with minimal risk of hypoglycemia. 
Keywords  Subcutaneous Insulin, Electronic, Critical 
Care 
 
1. Introduction 
Hyperglycemia in the critical care setting has shown to 
contribute to increased morbidity and mortality and canlead 
to multiple complications such as increased risk of infection, 
increased mechanical ventilation time, changes in 
hemodynamics, and changes in renal function [1, 2]. The 
American Association of Clinical Endocrinologists and 
American Diabetes Association therefore recommend 
control of hyperglycemia in critically ill patients with 
threshold glucose of ≥180 mg/dL [3]. This consensus 
committee statement also recommends frequent glucose 
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monitoring to decrease hypoglycemia while achieving 
glucose control [3] since hypoglycemia itself can also have 
deleterious effects on the patient. 
Although many clinical trials have evaluated appropriate 
glucose goals in the ICU, controversy remains as to specific 
targets that would favor patient outcomes and decrease 
mortality in the critical care setting [4-5].Most studies 
evaluating the benefit of tight glucose control in the (ICU) 
have utilized intravenous (IV) insulin [3, 6-9]. We have 
published earlier, the results of our computerized Clarian 
GlucoStabilizer™ Intravenous Program (CGS-IV) 
demonstrating its effectiveness and safety in achieving and 
maintaining tight glucose targets in the ICU[10]. However, 
subcutaneous (SQ) insulin therapy continues to be used, 
primarily as sliding scale insulin (SSI)not only in non-ICU 
but also in critical care settings. In order to effectively 
control glucose with insulin therapy, three critical attributes 
need to be met: standardization of insulin dose calculation, 
timely checking of BG, and standardized insulin dose 
readjustment. If one or more of these attributes are not met, 
the potential for persistent hyperglycemiaor development of 
hypoglycemiamay result. Appropriate protocol selection and 
implementation therefore is vital to the success of any 
glucose management strategy.  
Following the demonstrated safety and efficacy of the 
CGS-IV program, we sought solutions to the challenges we 
were encountering in SQ insulin delivery. Paper Protocols 
promoting basal bolus insulin were introduced and were 
modestly successful.  There continued to be a demand for a 
more standardized solution to calculate and administer SQ 
insulin within the hospital system. In 2006, Clarian Health, 
now Indiana University Health (IUH), launched the Clarian 
GlucoStabilizer™ Subcutaneous Program (CGS-SQ), to 
meet this need. This is a computerized program developed to 
standardize SQ insulin administration and reduce calculation 
errors [11].The program can be used to recommend most 
aspects of SQ insulin dosing including individual: prandial 
insulin doses, correction insulin doses, and treatment for 
hypoglycemia. The program is initiated by the practitioner, 
and enhances compliance with audible and visual reminder 
alarms for glucose testing [11]. Each insulin dose is 
administered SQ by the patient’s nurse, in response to 
prompts from the program.  The CGS-SQ has traditionally 
been utilized in non-critically ill patients; however, in recent 
years the program has also found acceptance inthe ICU.  
The objective of this study was to evaluate the efficacy and 
safety of the Clarian SQ GlucoStabilizer on glycemic control 
in the ICU. 
2. Methods 
This study is a retrospective data analysis evaluating the 
efficacy and safety of SQ insulin administration utilizing the 
CGS-SQ on glycemic control in the ICU. The study included 
data collected at two large academic medical centers, 
University Hospital (UH) and Methodist Hospital (MH) in 
Indianapolis, Indiana from January 1, 2009 to June 30, 2009. 
Details of the CGS –SQ has been described elsewhere [11].  
Briefly, once the practitioner orders SQ insulin via a 
standardized order set, the nurse initiates the computerized 
program. The program utilizes insulin sensitivity factors 
(ISF), carbohydrate ratios (CR), and blood glucose (BG) 
testing every three hours orevery four hours to facilitate 
rapid-acting insulin dose calculation and administration. ISF 
is the estimated reduction in BG that would occur with one 
unit of rapid-acting insulin. CR is the estimated number of 
grams of carbohydrate covered by one unit of rapid-acting 
insulin. The practitioner can use one of the available default 
settings for these parameters (ISF 60, CR 15; ISF 30, CR 10 
and ISF 15, CR 8). These default settings are based on body 
weight and were decided upon based on a consensus of 
physicians, pharmacists and nurses with experience in 
inpatient hyperglycemia management.  If a patient weighs 
less than 68 kg the default setting is an ISF 60, CR 15 and if 
68 kg or greater an ISF 30, CR 10 is the default. An ISF 15, 
CR 8 setting is also available and can be chosen by the 
treating practitioner based on the patient’s perceived insulin 
needs.  In addition, the treating practitioner has the ability to 
customize practitioner defined settings (PDS) for ISF or CR. 
The nurse enters the selected parameters into the software 
along with the starting BG value and the program clock is 
initiated. Glucose is tested every 3 or 4 hours, depending on 
the order set used.At MH, the order set utilizes 3 hour 
glucose testing while at UH a 4 hour glucose testing 
frequency is the default. The timings of 3 or 4 hours for 
glucose testing were based on a consensus similar to the ISF 
and CR calculations.  In addition the program sets a default 
BG target range of 100-150 mg /dL and the ISF is designed 
to target to the mid-point of this target range. Practitioners 
are able to modify the target range to suit their patient’s 
particular needs. 
When the program alarm (visual and audible) initiates for 
glucose testing, the treating nurse uses a point of care device 
to obtain a glucose reading, which is entered into the 
computer program. The program then determines the amount 
of insulin to be administered based on the patient’s glucose 
reading, target glucose range, ISF, and CR. For prandial 
insulin dosing, the program calculates a dose of rapid-acting 
insulin utilizing the total number of grams of carbohydrate 
consumed in the meal or bolus tube feeding.  For correction 
insulin dosing, the program calculates a dose of rapid-acting 
insulin based on the current BG and the midpoint of the 
target range using the ISF. Hypoglycemia recovery 
instructions include a standardized dose of dextrose 50% or 
grams of oral carbohydrates to be administered followed by 
BG testing every 15 minutes until the BG is ≥70 mg/dL. 
Numerous safeguards are built into the software such as 
alerts for potentially unsafe insulin doses and criteria for 
calling the practitioner [11].Guidelines for basal insulin 
administration are not part of the current version of the 
software; this insulin is administered separately based on 
practitioner instructions.   
In this study, comparison of initial ISF, CR, and frequency 
of glucose testing were evaluated to determine the most 
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appropriate initial program settings. Patients were identified 
through the CGS-SQ database along with the hospital patient 
database. All adult patients, 18 years of age or older, 
admitted to an ICU and initiated on the CGS-SQ program 
were screened but data was only analyzed for those patients 
in whom the practitioner had selected a target BG range of 
100-150 mg/dL which was standard of care at MH and UH 
during the study period. Patients were excluded if they 
received IV insulin while in the ICU.  This study included a 
mixed ICU population including: medical, surgical, 
cardiovascular, trauma, neurosurgical, pulmonary, bone 
marrow transplant, and solid organ transplant patients.  
Patients were categorized into one of four groups based on 
initial ISF and CR settings. Patients either had one of three 
predefined ISF and CR settings (ISF 60, CR 15; ISF 30, CR 
10; ISF 15, CR 8) or PDS for ISF and CR.  
The primary endpoints included: time to target glucose 
range, time in target glucose range, mean ICU glucose, 
hyperglycemic events, hypoglycemic events, and frequency 
of glucose testing. To evaluate hyperglycemic events, blood 
glucose values were studied in intervals of 10 mg/dL starting 
at ≥ 150 mg/dL to ≥ 250 mg/dL. Hypoglycemic events were 
also studied at decrements of 10 mg/dL starting at ≤ 70 
mg/dL to ≤ 40 mg/dL.  
2.1. Statistical Analysis 
Time in target glucose range and mean glucose were 
compared between the four treatment groups using 
ANOVA while hyperglycemic and hypoglycemic events 
were analyzed using Chi-Square analysis. The time to 
achieving target glucose range in each group was compared 
using Mantel-Cox analysis. A p-value of < 0.05 was  
established as statistically significant. 
3. Results 
During the 6 month study period, 1,384 patients met the 
inclusion criteria. A total of 34,514 blood glucose 
measurements were recorded. Seven hundred seventy-one 
patients (56%) had initial blood glucose readings outside 
their target glucose range (100-150 mg/dl); in the remainder, 
the program was initiated by the practitioner presumably to 
keep BG in target of 100-150 mg/dl during the ICU stay.  
For those patients with initial BG outside the target range at 
program initiation, the mean admission glucose was 174.1 ± 
62.2 mg/dL and the mean time to achieving the target of 
100-150 mg/dl was 18.5 ± 1.37 hours (median 9.23 ± 0.43 
hours). The mean glucose after achieving target was 137 ± 
28.7 mg/dL.  For those in the target range on admission, the 
mean admission glucose was 126.1 ± 14.0 mg/dL and the 
mean glucose while in the ICU was 131.8 ± 26.1 mg/dL. 
Patients initiated with one of the predefined settings had a 
shorter time to achieving the target glucose range compared 
to practitioner defined settings (Table 1). Patients in the ISF 
15, CR 8 group had the shortest mean time to target range of 
11.2 hours (median 6.9 hours). Overall, 81 patients (10.5%) 
did notachieve the target range of 100-150 mg/dl during their 
treatment in the ICU with the CGS-SQ.  
Patients initiated with one of the predefined settings spent 
more time within the target glucose range (ISF 60, CR 15:  
52% vs. ISF 30, CR 10: 46% vs. ISF 15, CR 8: 54 % vs. PDS: 
40%; p < 0.0001 Table 1). In addition, mean glucose within 
the default groups was lower than the PDS group (ISF 60, 
CR 15: 135 mg/dL vs. ISF 30, CR 10: 140 mg/dL vs. ISF 15, 
CR 8: 134 mg/dL vs. PDS: 143 mg/dL; p < 0.01).  
Table 1.  Target Glucose Attainment 
 ISF 60, CR 15 
(n=106) 
ISF 30, CR10 
(n=374) 
ISF 15, CR 8 
(n=193) 
PDS 
(n=98) p-value 
Patients initially 
out of range who 
reached target 
98 (92%) 322 (86%) 182 (94%) 88 (90%) *p<0.001 
Median time to 
target range 
100-150 mg/dL 
(hrs) 
11.1 10.1 6.9 14.5 *p<0.001 
Time in range 52% 46% 54% 40% 
†p<0.01 
*Comparison between all groups 
† Each group compared to PDS 
The frequency of hyperglycemia was evaluated in all patients, including those initially within the target BG range and 
those initially outside of the target BG range. Evaluation started at measurements of blood glucose ≥ 150 mg/dL and then in 
10 mg/dL increments up to ≥ 250 mg/dL. The overall frequency of hyperglycemia (BG ≥150 mg/dL) was 24.5% (n=8,442 
BG measurements). Patients initiated with one of the default settings had fewer hyperglycemic events compared to 
practitioner initiated settings (Table 2).  The ISF 15, CR 8 group had the fewest hyperglycemic events with 21.4% of 
measurements being ≥ 150 mg/dL and 0.8% being ≥ 250 mg/dL. 
The frequency of hypoglycemia was also evaluated in all patients. Measurements were evaluated starting at a blood 
glucose of ≤ 70 mg/dL and then in 10 mg/dL decrements down to severe hypoglycemia of ≤ 40 mg/dL. The overall incidence 
of hypoglycemia (BG ≤ 70 mg/dL) was low at 1.1% (n=368/34,514 BG measurements). Patients initiated with one of the 
 
32  Use of a Subcutaneous Insulin Computerized GlucoStabilizer™ Program on Glycemic Control  
  in the Intensive Care Setting: a Retrospective Data Analysis 
default settings had a lower incidence of hypoglycemia compared to PDS settings (Table 2). The incidence of severe 
hypoglycemia (BG ≤ 40 mg/dL) was extremely low (0.1% of all readings) (Table 2). On a per patient basis, patients with PDS 
experienced more hypoglycemia 0.38 events/patient (Table 3).   
Table 2.  Blood Glucose Measurements 
 ISF 60, CR 15 (n=191) 
ISF 30, CR 10 
(n=656) 
ISF 15, CR 8 
(n=374) 
PDS 
(n=163) 
*p-value 
Hypoglycemia 
Measurements  
≤ 70 mg/dL 0.9% 0.9% 1.2% 1.3% NS 
Measurements  
 ≤ 60 mg/dL 0.3% 0.3% 0.5% 0.6% NS 
Measurements 
  ≤ 50 mg/dL 0.1% 0.1% 0.2% 0.1% NS 
Measurements 
 ≤ 40 mg/dL 0% 0% 0.1% 0% NS 
Hyperglycemia 
Measurements ≥ 
150 mg/dL 22.7% 26.5% 21.4% 29.7% p<0.01 
Measurements ≥ 
160 mg/dL 17.4% 20.2% 15.2% 23.1% p<0.01 
Measurements ≥ 
170 mg/dL 13.4% 15.2% 10.7% 18.6% p<0.01 
Measurements ≥ 
180 mg/dL 9.6% 11.5% 7.4% 14.3% p<0.01 
Measurements ≥ 
190 mg/dL 7.3% 8.9% 5.1% 11.4% p<0.01 
Measurements ≥ 
200 mg/dL 5.6% 6.9% 3.6% 9.3% p<0.01 
Measurements ≥ 
210 mg/dL 4.2% 5.2% 2.6% 7.3% p<0.01 
Measurements ≥ 
220 mg/dL 3.2% 4.1% 2.0% 6.2% p<0.01 
Measurements ≥ 
230 mg/dL 2.4% 3.1% 1.5% 4.8% p<0.01 
Measurements ≥ 
240 mg/dL 1.8% 2.5% 1.1% 3.9% p<0.01 
Measurements ≥ 
250 mg/dL 1.4% 2.0% 0.8% 3.1% p<0.01 
*Each default setting compared to the PDS group 
NS = not significant 
Table 3.  Hypoglycemic Events 
*ISF 30, CR 10 compared to PDS. No difference found between other groups. 
†ISF 60, CR 15 and ISF 30, CR 10 compared to PDS. No difference found between other groups.  
 ISF 60, CR 15 (n=191) 
ISF 30, CR 10 
(n=656) 
ISF 15, CR 8 
(n=374) 
PDS 
(n=163) p-value 
Patients with 
hypoglycemia      
(BG ≤ 70 mg/dL) 
11% 9% 15% 19% *p<0.01 
Mean episodes of 
hypoglycemia per 
patient 
0.21 0.20 0.36 0.38 †p<0.01 
Total number of 
hypoglycemic events 
(BG ≤ 70 mg/dL)  
40 131 135 62 -- 
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The relationship of frequency of glucose testing to the efficacy and safety of the program was also evaluated. Patients who 
had every 3 hour glucose testing, irrespective of ISF or CR settings, had a shorter time to target glucose range, more time 
spent within the target glucose range, lower mean glucose, and decreased frequency of hyperglycemia (Table 4). 
Table 4.  Frequency of Glucose Testing 
 Every 3 hours Every 4 hours PDS *p-value 
Time to target range (hrs) 10.5 17.4 22.2 p<0.01 
% of time in target range 57% 52% 32% p<0.01 
Mean glucose (mg/dL) 132 ± 34 137 ± 39 149 ± 52 p<0.01 
Measurements ≥ 150 mg/dL 19.5% 24.6% 32.9% p<0.01 
Measurements ≤ 70 mg/dL 1.1% 1% 1.4% NS 
*Comparison between every 3 hours and every 4 hours compared to PDS 
NS = not significant 
4. Discussion 
Subcutaneous insulin delivery in the hospital has its 
challenges but is still the preferred route of insulin delivery. 
The first challenge is effectively getting patients within a 
preset glucose target.  Our data shows that with the Clarian 
SQ GlucoStabilizer (CGS-SQ) mean time to target of 
100-150 mg/dl was 18.5 hours (median 9.2 hours), 
percentage of hyperglycemic BG readings (≥ 150 mg/dL) 
24.5%, and mean BG after target achieved 137 ± 28 mg/dL. 
When we compare this to our efficacy outcomes of the 
Clarian IV GlucoStabilizer, the mean time to target of 
80-110 mg/dLwas 6.9 hours (median 6 hours); percentage of 
hyperglycemic BG readings (≥150 mg/dL) 8.0 %; and mean 
BG after target achieved 98.1 mg/dL [10].  When 
comparing the two programs, it is important to note 
differences in goal blood glucose ranges and insulin 
administration.  However, if we look individually at each 
ISF and CR setting, it differs; for example, the mean for ISF 
15, CR 8 mean time to target was only 11 hours. These data 
suggest that both the IV and SQ CGS programs are 
efficacious in correcting BG in critically ill patients.  
Regarding safety, the CGS-IV resulted in 3.5% of the BG 
readings ≤ 70 mg/dL, while only 0.4% were ≤ 50 mg/dL. The 
hypoglycemic events for the CGS-SQ were 1% ≤ 70 mg/dL, 
0.4% ≤ 60 mg/dl, 0.1% ≤ 50mg/dL and only 0.04% ≤ 40 
mg/dL. These data suggest that although there is a greater 
risk of hypoglycemia with IV insulin, the risk of severe, life 
threatening hypoglycemia is not different in the ICU when 
computerized IV or SQ insulin dosing tools are used.  
The target BG used in our institution with the CGS-SQ 
was far more stringent than those recommended by the 
AACE/ADA consensus panel [3], in whose opinion a BG 
range of 140-180 mg/dL is more acceptable for most 
institutions.Amongst the concerns that led the consensus 
panel [3] to raise their recommended targets from the earlier 
80-110 mg/dL were the potential for increase in mortality 
thought to be contributed, at least in part, by the risk of 
hypoglycemia when trying to achieve tight glucose control.  
Our data earlier with the CGS-IV [10], and now with the 
CGS-SQ, however clearly demonstrates that tighter glucose 
control can be achieved with minimal risk of hypoglycemia 
in the critically ill patient, if one uses computer driven 
insulin administration algorithms.  
Our study does have limitations. It is a retrospective 
evaluation of data, and not a randomized controlled trial. 
However, this is an analysis of data from a real world ICU 
setting where treating practitioners were making the clinical 
decision to use SQ insulin for their patients. The CGS-SQ is 
a computerized tool that offered them a means to standardize 
dose calculations and, after initiation, ensure compliance in 
insulin delivery and glucose testing.  In addition to 
standardization, the computerized program offers additional 
advantages over a paper based SSI insulin regimen, assisting 
in nursing reminders and hypoglycemia protocols. As 
such,this meaningful analysis is able to demonstrate that 
when treating practitioners use a computer program, safe and 
effective SQ insulin delivery is possible even in the ICU.  
Another potential limitation is documentation of basal 
insulin administration. Because of the limitations within our 
data collection software, we were not able to determine 
which of the patients included in our study received basal 
insulin. Anecdotally, however, we know that the vast 
majority of the patients in our institution are treated with 
both basal and bolus insulin regimens.Lastly, although the 
study was conducted in two different hospitals, both 
hospitals belong to the same health care system with a 
sharing of resources and staff. There is long standing 
glycemic control initiative in these institutions; the 
Systematic Utilization of Glucose Assessment and Response 
(SUGAR™) Program [11-13] with heightened awareness 
towards insulin treatment and aggressive monitoring of BG 
which could have influenced the results. However, part of 
the reason for the heightened awareness is the CGS programs 
themselves and their associated alarm functions which 
facilitate better care. Having the study repeated therefore in 
other institutions where such a heightened awareness does 
not exist may be of benefit. 
Irrespective of targets for glucose control, insulin is the 
only safe and recommended means of managing hospital 
hyperglycemia [3]. This drug however continues to remain a 
high-alert medication and therefore standardization of 
insulin delivery is of paramount importance [14]. Our data 
show the reminder systems and standardized dosage 
calculations, integral to the software of the CGS-SQ, provide 
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a safe and effective means for reducing insulin 
administration errors. Given that over 35% of the patients 
being admitted to the hospital manifest hyperglycemia [15] it 
is imperative that we have safe and effective insulin delivery 
systems for the practitioners to use. The CGS-SQ has been 
shown to be safe and effective now, not only in the 
non-critically ill [11] but also in the treatment of the ICU 
patient. 
5. Conclusion 
The mainstay treatment of hyperglycemia in the ICU has 
always been IV insulin which is a very labor intensive 
process. The Clarian GlucoStabilizer (CGS-SQ) is the first 
software program that has evaluated the effectiveness of SQ 
insulin in the treatment of the critically ill patient. Our study 
has shown that by using a system of computerized prompts 
with standardization of insulin dose calculation and reminder 
alarms, SQ insulin can be effectively used in the treatment of 
ICU patients to target BG of 100-150 mg/dL with minimal 
risk of hypoglycemia.  
This study offers a critical insight into the safety and 
effectiveness of SQ insulin use in the ICU.  Data from this 
analysis demonstrates the CGS-SQ can be used to design 
future randomized clinical trials, where the variability 
created by different insulin protocols can be minimized 
allowing for a true testing of the hypothesis of the 
effectiveness of tight glucose control and its effects on 
outcomes of morbidity and mortality in the critically ill 
patient.   
6. Key Messages 
• Hyperglycemia in the critical care setting has shown to 
contribute to increased morbidity and mortality and canlead 
to multiple complications.  
• The Clarian GlucoStabilizer™ Subcutaneous Program is 
a computer program utilizing insulin sensitivity factors, 
carbohydrate ratios, and every three or four hour blood 
glucose  testing to facilitate rapid-acting insulin dose 
calculation and administration. 
• In our current study, the Clarian GlucoStabilizer™ 
Subcutaneous Program resulted in a mean blood glucose of 
137 mg/dL with a median time to target glucose range of 9.2 
hours.  
• Using a system of computerized prompts with 
standardization of insulin dose calculation, subcutaneous 
insulin can be effectively used in the treatment of ICU 
patients to target blood glucose of 100-150 mg/dL with 
minimal risk of hypoglycemia. 
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